Pneumonia. End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group: 25 patients received 13 valent anti pneumococcal vaccine, after 8 weeks received 23 valent vaccine. Intervention 2: Control group: 25 patients receive 23 valent vac
Sponsors
Research deputy of Shahid Beheshti Medical Science
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients who have been started hemodialysis at least 3 months All patients who have been dialysed at least three times a week All patients who have at least 16 years old
Exclusion criteria
Exclusion criteria: Immunocompromised use immunosuppresive agents Spleen function impairment HIV infection Malignancies bone marrow transplantation history of previous injection of pneumococcal vaccine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-pneumococcal antibody titer. Timepoint: 1 month and 6 months after vaccination. Method of measurement: Human Anti-S. Pneumococcal vaccine (Pneumovax/CPS23) IgG ELISA Kit; (23 serotypes: 1, 2, 3, 4, 5, 6b, 7F, 8,9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F), quantitative. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of anti-pneumococcal antibody titre constancy. Timepoint: One month and six months after the date of the 23 valent polysaccharide vaccination. Method of measurement: To determine the antibody titer and ELIZA test, The antibody titre will be measured with a specific kit (Copper Serum / Plasma). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShima Shahi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed